Omayma Abidi^1,2* and Ouajdi Souilem^2,3

¹Faculty of Sciences of Tunis, University Tunis El Manar, Tunisia
²Laboratory of Physiology and Pharmacology, National School of Veterinary Medicine, University of Manouba, Sidi Thabet, Ariana, Tunisia
³BiotechPole, Sidi Thabet, Ariana

*Corresponding Author: Omayma Abidi, Faculty of Sciences of Tunis, University Tunis El Manar and Laboratory of Physiology and Pharmacology, National School of Veterinary Medicine, University of Manouba, Sidi Thabet, Ariana, Tunisia

Received: June 30, 2025; Published: July 15, 2025

Abstract

Breast cancer remains a major public health concern worldwide, with high incidence and mortality rates among women. While conventional treatments such as surgery, chemotherapy, radiotherapy, hormone therapy, and targeted therapy have significantly improved patient outcomes, limitations including resistance, recurrence, and adverse effects persist.

This review aims to explore the current landscape of breast cancer therapies both conventional and innovative and to assess the potential role of phytotherapy as an adjuvant in treatment strategies.

A comprehensive literature analysis was conducted, focusing on the mechanisms, efficacy, and limitations of standard and emerging therapeutic approaches. Special attention was given to plant-derived compounds with demonstrated anti-breast cancer activity in preclinical and clinical studies.

Innovative therapies, including immunotherapy, gene therapy, and nanotechnology-based treatments, offer promising avenues for more personalized and effective care. In parallel, several medicinal plants and their bioactive compounds such as Pistacia lentiscus, Curcuma longa, and Camellia sinensis have shown potential in enhancing therapeutic efficacy, reducing side effects, and targeting cancer pathways.

Phytotherapy, when integrated with evidence-based medicine, holds promise as a complementary strategy in breast cancer treatment. Further clinical research is essential to validate its safety, efficacy, and optimal use alongside conventional and innovative therapies.

Keywords: Breast Cancer; Chemotherapy; Radiotherapy; Innovative Therapy; Phytotherapy; Adjuvant Treatment; Medicinal Plants

References

1. Yapo V., et al. “Epidemiological, Clinical, Radiological and Histopathological Aspects of Female Breast Cancer in the Gbêkê Region (Bouaké)”. CellBio 2 (2020): 13-22.
2. Sharma GN., et al. “Various types and management of breast cancer: an overview”. Journal of Advanced Pharmaceutical Technology and Research2 (2010): 109.
3. National_Institut_of_Cancer (2022).
4. Abidi O., et al. “Phytochemical analysis and biological activities of two oil-bearing extracts from fresh Pistacia lentiscus”. Bulletin of the Chemical Society of Ethiopia6 (2023): 1487-1501.
5. Abidi O., et al. “Pistacia lentiscus L. revealed in vitro anti-proliferative activity on MCF-7 breast cancer cells and in vivo anti-mammary cancer effect on C57BL/6 mice through necrosis, anti-inflammatory and antioxidant enhancements”. Plos One4 (2024): e0301524.
6. Ali SA., et al. “Potential therapeutic applications of phytoconstituents as immunomodulators: Pre‐clinical and clinical evidences”. Phytotherapy Research 7 (2021): 3702-3731.
7. Fiorentino S., et al. “Phyto-immunotherapy, a complementary therapeutic option to decrease metastasis and attack breast cancer stem cells”. Frontiers in Oncology 10 (2020): 1334.
8. Li S., et al. “Chinese herbal medicine for reducing chemotherapy-associated side-effects in breast cancer patients: a systematic review and meta-analysis”. Frontiers in Oncology 10 (2020): 599073.
9. Drãgãnescu M and C Carmocan. “Hormone therapy in breast cancer”. Chirurgia4 (2017): (2024): 413-417.
10. Abraham J and J Staffurth. “Hormonal therapy for cancer”. Medicine 1 (2016): 30-33.
11. Litton, J., et al. “Tamoxifen therapy for patients with breast cancer”. The Lancet9883 (2013): 2077-2078.
12. Espié M. “Inhibiteurs de CDK4/6 et cancers du sein, du métastatique à l’adjuvant: données cliniques”. Innovations and Thérapeutiques en Oncologie3 (2022): 157-165.
13. Coussy F. “Identification of New Targeted Therapeutic Strategies for the Management of Breast Cancer Using a Large Panel of Patient-Derived Xenografts. 2019, Université Paris Saclay (COmUE) (2019).
14. Le Du F., et al. “Therapeutic innovations in breast cancer”. La Presse Médicale10 (2019): 1131-1137.
15. Cuppen E., et al. “Implementation of whole-genome and transcriptome sequencing into clinical cancer care”. JCO Precision Oncology 6 (2022): e2200245.
16. Catros V. “Les CAR-T cells, des cellules tueuses spécifiques d’antigènes tumoraux-De nouvelles générations pour le traitement des tumeurs solides”. Médecine/Sciences 4 (2019): 316-326.
17. Nalawade SA., et al. “Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer”. Journal for Immunotherapy of Cancer11 (2021).
18. Bardia A., et al. “The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) advanced/metastatic breast cancer”. Breast Cancer Research and Treatment2 (2023): 319-331.
19. Alamri AH., et al. “Enhancing plant-derived smart nano inhibitor in targeting mammalian target of rapamycin (mTOR) in breast cancer using Curcuma longa-derived compound curcumin”. Environmental Science and Pollution Research (2023): 1-8.
20. McGrowder DA., et al. “Medicinal herbs used in traditional management of breast cancer: Mechanisms of action”. Medicines8 (2020): 47.
21. Wong JH., et al. “Mushroom extracts and compounds with suppressive action on breast cancer: Evidence from studies using cultured cancer cells, tumor-bearing animals, and clinical trials”. Applied Microbiology and Biotechnology 104 (2020): 4675-4703.
22. Tubéry P., et al. “Desmodium adscendens. De l’usage traditionnel camerounais contre les hépatites à l’accompagnement des chimiothérapies”. Hegel4 (2015): 268-282.
23. SASSI Zineb TM. “Evaluation de l’effet protecteur de l’extrait de Ginkgo Biloba sur les perturbations biochimiques et neurobiologique induits par le stress chronique de contention chez un model animal. 2023, Université Echahid Chikh Larbi Tebessi-Tebessa (2023).
24. Calaf GM., et al. “Curcumin and paclitaxel induce cell death in breast cancer cell lines”. Oncology Reports4 (2018): 2381-2388.
25. Kamble SS and RN Gacche. “Evaluation of anti-breast cancer, anti-angiogenic and antioxidant properties of selected medicinal plants”. European Journal of Integrative Medicine 25 (2019): 13-19.
26. Jenča A., et al. “Herbal therapies for cancer treatment: A review of phytotherapeutic efficacy”. Biologics: Targets and Therapy (2024): 229-255.

Citation

Citation: Omayma Abidi and Ouajdi Souilem. “Adjuvant Phytotherapy in Breast Cancer: A New Player in Conventional and Innovative Treatment Strategies?".Acta Scientific Nutritional Health 9.8 (2025): 37-44.

Copyright

Copyright: © 2025 Omayma Abidi and Ouajdi Souilem. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.